Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L Coleman*, Domenica Lorusso, Christine Gennigens, Antonio González-Martín, Leslie Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frederic Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R Harris, Margaret Smith, Leonardo Viana Nicacio, Melinda S L Teng, Annouschka Laenen, Reshma Rangwala, Luis MansoMansoor Mirza, Bradley J Monk, Ignace Vergote, The innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators

*Corresponding author

Research output: Contribution to journalJournal articlepeer-review

4 Citations (Scopus)
Original languageEnglish
JournalThe Lancet Oncology
Volume22
Issue number5
Pages (from-to)609-619
Number of pages11
ISSN1470-2045
DOIs
Publication statusPublished - 1 May 2021

Fingerprint

Dive into the research topics of 'Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study'. Together they form a unique fingerprint.

Cite this